BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Sunday. The firm issued a sell rating on the medical technology company’s stock.

Other research analysts also recently issued reports about the company. Ascendiant Capital Markets cut their price objective on BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Benchmark restated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Up 12.0 %

BIOL stock opened at $0.01 on Friday. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94. The firm has a 50 day moving average of $0.01 and a two-hundred day moving average of $0.05. The company has a market capitalization of $280,618.80, a price-to-earnings ratio of 0.00 and a beta of 0.67.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.